We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Scope Fluidics’ Microfluidic Antimicrobial Susceptibility System Obtains European CE IVD Marking Approval

By LabMedica International staff writers
Posted on 29 Oct 2021
Print article
Image: BacterOMIC system (Photo courtesy of Scope Fluidics)
Image: BacterOMIC system (Photo courtesy of Scope Fluidics)

Scope Fluidics’ (Warsaw, Poland) BacterOMIC microfluidic antimicrobial susceptibility system has received a European CE marking certificate for in vitro diagnostic devices, which approves it for use on the European Union market.

The BacterOMIC system allows for the identification in a single test of the effectiveness of a range of 20 antibiotics that are used in the treatment of, among others, infections of the respiratory tract, blood, urinary tract, or skin, caused by the Enterobacterales; Pseudomonas; Acinetobacter, Staphylococcus bacteria. The system makes it possible to assess the treatment effectiveness for the following antibiotics, all in one test: amoxicillin, cefuroxime, cefazolin, tobramycin, amikacin, azithromycin, ceftazidime, ceftazidime with avibactam, ciprofloxacin, clindamycin, ceftriaxone, cefotaxime, cefepime, moxifloxacin, norfloxacin, ofloxacin, piperacillin, piperacillin with tazobactam, trimethoprim, trimethoprim with sulfamethoxazole.

The modern diagnostic device has undergone clinical tests of the first diagnostic panel. The tests confirmed the functionality of the BacterOMIC system in diagnosing the drug susceptibility of bacteria causing a number of infections, including in the respiratory system, blood, urinary tract and skin. During specialized tests carried out in independent clinical centers, the system achieved over 90% compliance in the drug susceptibility assessment for 20 antibiotics which were assigned to one of the two resistance categories: resistant/susceptible. The company plans to expand the system with more antibiotics in order to make full use of the system’s diagnostic capabilities.

“BacterOMIC is a system with a very large market potential, which has a chance to revolutionize antibiotic treatment,” said Marcin Izydorzak, Vice President and one of the founders of Scope Fluidics. “Today, the needs of doctors and their patients in this area are enormous. Experts estimate that the market for automated antimicrobial susceptibility testing is worth approximately USD1 billion annually. Clinical tests have proven the efficiency of the BacterOMIC system, which ultimately might be able to test all clinically significant antibiotics in one test.”

“BacterOMIC is an exceptional solution on a world scale, and ultimately it is intended to allow us to check up to 640 bacteria cultivation conditions in one test,” added Dr. Seweryn Bajer-Borstyn, head of the BacterOMIC project in the Scope Fluidics Group. “This will translate into the possibility of creating a single test to cover most clinically used antibiotics. We are happy that our work on all the aspects of the system were confirmed in the clinical tests of the first BacterOMIC diagnostic panel.”

Related Links:
Scope Fluidics 

Gold Supplier
Molecular Diagnostic System
Integrated Urinalysis Chemistry Analyzer
Automated Nucleic Acid Extraction System
Portable Tube Luminometer
Junior LB 9509

Print article
IIR Middle East


Molecular Diagnostics

view channel

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more


view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.